Amiselimod HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319538

CAS#: 942398-84-7 (HCl)

Description: Amiselimod, also known as MT1303, is a potent and selective immunosuppressant and sphingosine 1 phosphate receptor modulator. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.

Chemical Structure

Amiselimod HCl
CAS# 942398-84-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 319538
Name: Amiselimod HCl
CAS#: 942398-84-7 (HCl)
Chemical Formula: C19H31ClF3NO3
Exact Mass:
Molecular Weight: 413.91
Elemental Analysis: C, 55.14; H, 7.55; Cl, 8.56; F, 13.77; N, 3.38; O, 11.60

Price and Availability

Size Price Availability Quantity
10.0mg USD 90.0 Same Day
25.0mg USD 190.0 Same Day
50.0mg USD 350.0 Same Day
100.0mg USD 550.0 Same Day
200.0mg USD 950.0 Same Day
500.0mg USD 1950.0 Same Day
1.0g USD 2950.0 Same Day
2.0g USD 5250.0 Same Day
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 942399-20-4 (free base)   942398-84-7 (HCl)    

Synonym: MT-1303; MT1303; MT 1303; Amiselimod HCl; Amiselimod Hydrochloride

IUPAC/Chemical Name: 2-amino-2-{2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl}propane-1,3-diol hydrochloride


InChi Code: InChI=1S/C19H30F3NO3.ClH/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25;/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3;1H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 413.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol. 2019 Mar 13;10:212. doi: 10.3389/fphar.2019.00212. eCollection 2019. Review. PubMed PMID: 30930775; PubMed Central PMCID: PMC6425155.

2: Kifuji T, Inoue S, Furukawa M, Madera BP, Goto T, Kumagai H, Mair SJ, Kawaguchi A. Absorption, Disposition and Metabolic Pathway of Amiselimod (MT-1303) in Healthy Volunteers in a Mass Balance Study. Xenobiotica. 2018 Sep 20:1-54. doi: 10.1080/00498254.2018.1525508. [Epub ahead of print] PubMed PMID: 30231665.

3: Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 Jan 10;25(2):270-282. doi: 10.1093/ibd/izy269. PubMed PMID: 30165490; PubMed Central PMCID: PMC6327230.

4: Dash RP, Srinivas NR, Rais R. A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators. Biomed Chromatogr. 2018 Jan;32(1). doi: 10.1002/bmc.4109. Epub 2017 Nov 6. Review. PubMed PMID: 28990207.

5: Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T. Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15. PubMed PMID: 28911260; PubMed Central PMCID: PMC6196590.

6: Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2017 Oct;14(4):859-873. doi: 10.1007/s13311-017-0565-4. Review. PubMed PMID: 28812220; PubMed Central PMCID: PMC5722770.

7: Gusman DH, Shoemake C. Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis. Yale J Biol Med. 2017 Mar 29;90(1):15-23. eCollection 2017 Mar. PubMed PMID: 28356890; PubMed Central PMCID: PMC5369033.

8: Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017 May;16(5):495-503. doi: 10.1016/j.autrev.2017.03.007. Epub 2017 Mar 7. Review. PubMed PMID: 28279838.

9: Harada T, Wilbraham D, de La Borderie G, Inoue S, Bush J, Camm AJ. Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects. Br J Clin Pharmacol. 2017 May;83(5):1011-1027. doi: 10.1111/bcp.13203. Epub 2017 Jan 19. PubMed PMID: 27921320; PubMed Central PMCID: PMC5401982.

10: Sugahara K, Maeda Y, Shimano K, Mogami A, Kataoka H, Ogawa K, Hikida K, Kumagai H, Asayama M, Yamamoto T, Harada T, Ni P, Inoue S, Kawaguchi A. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15-27. doi: 10.1111/bph.13641. Epub 2016 Nov 17. PubMed PMID: 27714763; PubMed Central PMCID: PMC5221453.

11: Fyfe I. Multiple sclerosis: Successful trial of amiselimod for multiple sclerosis. Nat Rev Neurol. 2016 Oct;12(10):554. doi: 10.1038/nrneurol.2016.128. Epub 2016 Aug 26. PubMed PMID: 27562552.

12: Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16. PubMed PMID: 27543447.

13: Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs. 2016 Jun;25(6):709-18. doi: 10.1517/13543784.2016.1165204. Epub 2016 Mar 28. Review. PubMed PMID: 26967267.

Additional Information

Related CAS#
942398-84-7 ( Amiselimod hydrochloride);
942399-20-4 ( Amiselimod free base).